Share on StockTwits

Stock analysts at Jefferies Group began coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE) in a report issued on Friday. The firm set a “buy” rating and a $14.00 price target on the stock. Jefferies Group’s price objective would suggest a potential upside of 75.88% from the stock’s previous close.

Ampio Pharmaceuticals (NYSE:AMPE) traded up 3.02% on Friday, hitting $8.20. The stock had a trading volume of 594,213 shares. Ampio Pharmaceuticals has a 1-year low of $5.06 and a 1-year high of $10.86. The stock’s 50-day moving average is $7.43 and its 200-day moving average is $7.29. The company’s market cap is $425.7 million. Ampio Pharmaceuticals also was the target of a large increase in short interest in the month of June. As of June 13th, there was short interest totalling 6,009,356 shares, an increase of 6.3% from the May 30th total of 5,652,226 shares. Based on an average daily trading volume, of 412,648 shares, the days-to-cover ratio is currently 14.6 days. Currently, 12.4% of the company’s shares are short sold.

Separately, analysts at Citigroup Inc. initiated coverage on shares of Ampio Pharmaceuticals in a research note on Friday, May 9th. They set a “buy” rating on the stock.

Ampio Pharmaceuticals, Inc (NYSE:AMPE) is a development-stage biopharmaceutical company focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.